Obesity increases risk of prostate cancer recurrence, regardless of race

Article

Obesity plays no favorites when it comes to increasing the risk of prostate cancer recurrence after surgery, according to researchers at Duke University Medical Center, Durham, NC. Being overweight is equally bad for African-American and white men.

Obesity plays no favorites when it comes to increasing the risk of prostate cancer recurrence after surgery, according to researchers at Duke University Medical Center, Durham, NC. Being overweight is equally bad for African-American and white men.

Because African-Americans are more likely than whites to develop and die from prostate cancer and because there is a higher prevalence of obesity among African-American men with prostate cancer compared with white men, some studies have suggested that obesity might be a more ominous risk factor for African-American than white men.

"Not so," said Stephen Freedland, MD, senior author of the study, published in the Aug. 10 online Cancer. "Obesity leads to worse cancer in both groups."

Researchers examined the records of 1,415 men enrolled in the Shared Equal Access Regional Cancer Hospital (SEARCH) database who had undergone a radical prostatectomy. African-American men comprised 47% of the sample.

After adjusting for various preoperative characteristics, researchers analyzed the relationship between body mass index and cancer aggressiveness. In contrast to other studies, investigators found no association between race and obesity. Almost one-third of the men were obese, regardless of race.

Higher BMI was associated with significantly increased risk of cancer recurrence in both African-American and white men. Although obesity did not influence risk more in one race than another, it was identified as a risk factor for aggressive disease, regardless of race.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.